Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1031
Peer-review started: June 12, 2020
First decision: July 30, 2020
Revised: August 15, 2020
Accepted: September 18, 2020
Article in press: September 18, 2020
Published online: November 27, 2020
Processing time: 165 Days and 3.8 Hours
MicroRNAs (miRNAs) have been suggested as biomarkers for malignant diseases including hepatocellular carcinoma (HCC). Specifically, hsa-miR-21-5p (miR-21) is among the most frequently deregulated miRNA in cancer. The diagnostic and prognostic value of miR-21 has been demonstrated in HCC tissue, mostly in the Asian population. Although the impact of various factors has been recently reported for circulating hsa-miR-122-5p (miR-122), at present only limited knowledge is available for miR-21.
To evaluate the value of miR-21 for the assessment of prognosis in HCC patients and to delineate the influence of clinical and preanalytical factors on miR-21 level in sera.
Patients with confirmed HCC from our European cohort with predominantly alcohol-associated liver damage were included in the study. All subjects were characterized according to their clinical and laboratory work-up and overall survival data were obtained. Quantitative real-time polymerase chain reaction was performed for miR-21 and spiked-in cel-miR-39-3p. The results were compared to previously reported miR-122 data.
Survival of HCC patients was comparable between patients with low and high serum miR-21 concentration. No association was observed between miR-21 level in sera and Child-Pugh score, Barcelona Clinic Liver Cancer staging system, or etiology of HCC/liver disease. Age, gender, or pretreatment had no association with miR-21 level. A positive correlation was observed between miR-21 and aspartate aminotransferase (r = 0.2854, P = 0.0061), serum miR-122 (r = 0.2624, P = 0.0120), and the International Normalized Ratio (r = 0.2065, P = 0.0496). Negative correlation of miR-21 with serum creatinine (r = -0.2215, P = 0.0348) suggests renal function as a potential influencing factor in miR-21 biogenesis in blood.
The results from this work do not support clinically relevant prognostic value of circulating miR-21 in HCC patients in real-life settings. Following systematic evaluation, we identified renal function and aspartate aminotransferase as potential factors that may affect miR-21 concentration in blood. This knowledge should be considered in future miRNA-based biomarker studies not only for HCC but also for other diseases.
Core Tip: In our previous work, we identified renal function, hemoglobin, and liver injury as potential factors that may impact circulating microRNA expression. miR-21-5p is the most frequently deregulated miRNA in various types of cancer. Several reports have proposed miR-21-5p as a prognostic biomarker in hepatocellular carcinoma. In this study, serum miR-21-5p values were not associated with prognosis of hepatocellular carcinoma in a European cohort of patients with predominantly alcohol-related liver injury. In a similar fashion as previously reported for miR-122-5p, changes in circulating miR-21-5p level correlated with renal function and liver injury. This observation shows that caution should be taken in interpreting circulating miR-21-5p level and its biomarker potential.